AU
UK
CA
NZ
IND
US
Single-Patient Case Study Highlights Early Signal for Phyto-N in Cancer CachexiaCuranex Pharmaceuticals drew market attention after presenting a single-patient case study suggesting potential symptomatic benefits of its lead candidate, Phyto-N, in cancer cachexia and advanced cancer supportive care. The patient, treated for a pancreatic …
BioXcel Therapeutics has initiated patient enrollment in a Phase 2a clinical trial evaluating BXCL501 for acute stress reactions (ASR), marking a notable step in the company’s effort to expand its neuroscience pipeline. The study, funded by the U.S. Department of War and led by …
AI Nose Healthcare Deployment Signals Strategic Expansion into High-Value InfrastructureAinos, Inc. (NASDAQ: AIMD) has announced a partnership with MacKay Memorial Hospital and Topco Scientific to deploy its AI Nose technology across critical hospital environments. This move marks a notable extension of its Smell AI …
Capital Raising and Liquidity Position Strengthen Acquisition Pipeline
enGene Therapeutics Name Change Reflects Commercial Transition StrategyenGene’s decision to rebrand from enGene Holdings Inc. to enGene Therapeutics Inc. marks a strategic inflection point as the company moves closer to potential commercialization. The name change, effective April 8, 2026, aligns with its evolving identity …
Key HighlightsLNSR down 32.85% to $6.89 on March 17, 2026 merger termination announcement with AlconFTC opposition cited competitive concerns in femtosecond laser-assisted cataract surgery marketCompany retains $10 million merger deposit and refocuses on ALLY robotic cataract platform growthStrategy update and Q4 2025 earnings scheduled …
Key HighlightsCTMX stock down 19.26% to $5.45 despite positive Varseta-M colorectal cancer trial data showing 32% response ratesCompany reported $137M cash position with runway extending to Q2 2027, plus $250M secondary offering to fund developmentVarseta-M demonstrating clinical activity in CRC with FDA interactions planned …
Key HighlightsEDSA stock surges 36.72% to $7.00 following positive Phase 3 trial data and CEO insider purchases demonstrating management confidenceLead candidate EB05 monoclonal antibody in Phase 3 for acute respiratory distress syndrome (ARDS) with significant clinical unmet needEB01 topical cream completed Phase 3 clinical …
Key HighlightsBIAF stock up 43.46% today as CyPath testing revenue surges 87% year-over-year with 99% unit volume growthLarge-scale 2,000-patient longitudinal study underway at 20+ sites including VA centers and military hospitalsCompany raised $16.9M capital, ended 2025 with $6.5M cash to support expansion despite profitability …
Key HighlightsAgenus closed $141M strategic collaboration with Zydus Lifesciences including $75M cash upfront and $16M equity investmentBOT+BAL immunotherapy combination shows 17% objective response rate and 17.2 months median overall survival in MSS metastatic colorectal cancerFrance's ANSM approved expanded compassionate access protocol in January 2026 …
Please wait processing your request...